Michael L. Fantozzi
Member/Managing Member, Boston Office; Chair, Corporate, Tax, Private Client & Immigration Division
+1.617.348.1640
Michael is a leading corporate, securities, and mergers and acquisitions lawyer who leads deals that transform clients’ businesses. He helps buyers and sellers purchase and divest assets, divisions, or entire companies and counsels issuers in public offerings, often working on transactions valued at hundreds of millions of dollars.
Michael is a senior member of both the Securities Practice Group and the Mergers and Acquisitions Practice Group. He represents public and private companies with an emphasis on financing transactions, mergers and acquisitions, and corporate governance issues. Michael has extensive mergers and acquisitions experience as both purchaser’s and seller’s counsel, and he has represented issuers in numerous public offerings.
Michael also plays a vital role in firm management: he is Managing Member of the firm’s Boston office, serves on the firm’s Executive Committee and is the Division Head for the firm's Corporate, Tax, Private Client, and Immigration Sections.
Michael is a leading corporate, securities, and mergers and acquisitions lawyer who leads deals that transform clients’ businesses. He helps buyers and sellers purchase and divest assets, divisions, or entire companies and counsels issuers in public offerings, often working on transactions valued at hundreds of millions of dollars.
Experience
Mergers & Acquisitions
- Hyperfine, Inc.'s (Nasdaq: HYPR) business combination, valued at $580 million, with Liminal Sciences and the SPAC, HealthCor Catalio Acquisition Corp.
- The Metals Company’s (Nasdaq: TMC) (formerly DeepGreen Metals) business combination, valued at $2.9 billion, with the SPAC, Sustainable Opportunities Acquisition Corporation
- Azenta Life Sciences' (Nasdaq: AZTA) (formerly Brooks Automation, Inc.) $3 billion sale of its Semiconductor Solutions business to private equity firm Thomas H. Lee Partners, L.P.
- Optum’s acquisition of Atrius Health
- Quantum-SI’s (Nasdaq: QSI) $1.46 billion business combination with the SPAC, HighCape Capital Acquisition Corp.
- Butterfly Network’s (NYSE: BFLY) $1.5 billion business combination with the SPAC, Longview Acquisition Corp.
- QIAGEN in its proposed $12.5 billion sale to Thermo Fisher Scientific
- Brooks Automation’s approximately $450 million purchase of genomics service provider Genewiz Group
- Brooks Automation’s $675 million sale of its semiconductor cryogenics business to Edwards Vacuum LLC (a member of the Atlas Copco Group)
- John Hancock Financial Network’s sale of Signator Investors to Advisor Group
- Connance’s sale to Waystar Health
- Optum’s purchase of Reliant Medical Group
- Fidelity’s purchase of a software solutions company
- C&S Wholesale Grocers’ purchase of the assets of Davidson Co., Inc.
- Brooks Automation’s $127 million purchase of BioStorage Technologies
- John Hancock Financial Network’s purchase of the assets of Transamerica Financial Advisors
- Naurex’s sale to Allergan
- Leerink Swann’s sale of the assets of Leerink Swann Consulting to NCI Healthcare
- John Hancock Financial Network’s purchase of Symetra Investment Services
- C&S Wholesale Grocers’ purchase of the assets of Associated Wholesalers
- Humedica’s sale to UnitedHealth Group
- Piramal Healthcare Limited’s $635 million purchase of Decision Resources Group
- iMDsoft’s $60 million sale to TPG
- Ion Torrent Systems’ $725 million sale to Life Technologies
- Amicas’ $267 million sale to Merge Healthcare
- Vertex Pharmaceuticals’ $400 million purchase of ViroChem Pharma
- iBasis’ $100 million sale to Royal KPN
- Qiagen’s $1.6 billion purchase of Digene Corporation
Public Offerings
- Vertex Pharmaceuticals in over $2.5 billion in equity and debt offerings
Michael also serves as counsel to Brooks Automation and John Hancock Life Insurance Company. Private company clients include C&S Wholesale Grocers, LAM Therapeutics and W.E. Aubuchon Co.
Case Studies
Case Study
News & Press
Fifty-Nine Attorneys Recognized as 2023 Massachusetts Super Lawyers and Rising Stars
October 12, 2023
Mintz Named a Law360 2022 Powerhouse in Massachusetts
August 08, 2022
Massachusetts Powerhouse: Mintz
August 8, 2022
Massachusetts Powerhouse: Mintz
August 5, 2021
Mintz Recognized as 2021 Massachusetts Powerhouse by Law360
August 04, 2021
Mintz Publishes In-Depth Report Breaking Down the SPAC Surge
March 19, 2021
Mintz Atty On Steering Quantum-Si's $1.46B Go-Public Deal
February 23, 2021
Mintz Advises Quantum-SI in $1.46 Billion SPAC Merger
February 19, 2021
Mintz Practice Groups and Attorneys Garner Top Rankings in 2020 Edition of The Legal 500 United States
June 12, 2020
Massachusetts Powerhouse: Mintz Levin
August 30, 2018
Garrett M. Winslow Elevated to Member of Mintz
May 18, 2017
Mintz Attorney Susan M. Finegan Receives 2017 Woman of the Year Award from Women’s Law Center at Boston College Law School
April 24, 2017
Eighty-Four Mintz Attorneys Named 2016 Massachusetts Super Lawyers and Rising Stars
October 18, 2016
Mintz Represents Naurex Inc. in Merger with Allergan PLC
July 29, 2015
Mintz and LearnLaunch Announce Partnership
February 21, 2014
Events & Speaking
Let's Talk SPACs - SPACs Session 2: de-SPAC – So Now You’re a Public Company
HUB International
Webinar
New England Healthcare Executive Network Meeting
Special Purpose Acquisition Company ("SPAC") Impact On Medtech
Webinar
Michael is a leading corporate, securities, and mergers and acquisitions lawyer who leads deals that transform clients’ businesses. He helps buyers and sellers purchase and divest assets, divisions, or entire companies and counsels issuers in public offerings, often working on transactions valued at hundreds of millions of dollars.
Recognition & Awards
Best Lawyers in America: Securities /Capital Markets Law (2007 – 2024); Corporate Law (2007 – 2024); Corporate Governance Law (2007 - 2024).
Included on the Massachusetts Super Lawyers list: Securities & Corporate Finance (2004 – 2006, 2008 – 2018, 2022 – 2023)
Recommended by The Legal 500 United States for M&A: Middle-Market (2016 – 2017, 2020 – 2022); Capital Markets: Equity (2020 – 2022)
Recent Insights
